In 2016 R-Japan cultured and supplied a total of 1,055.9 billion stem
cells for 5 affiliated hospitals including Nishihara Clinic. The company
conducted regenerative medical treatment more than 3,500 times and
achieved sales of KRW10.4 billion as well as the ordinary profit of
The patients who received the regenerative medical treatment with stem
cells supplied by R-Japan did not have any side effects. This
performance of the medical treatment for the past 1 year has been
officially reported to Japan’s Ministry of Health, Labor and Welfare.
Moreover, the medical treatment’s effects regarding degenerative
arthritis, critical limb ischemia, autoimmune disease and skin care have
been gradually acknowledged. R-Japan reported the number of medical
treatments for degenerative arthritis exceeded 650 and the satisfaction
regarding its therapeutic effect was very high.
is promoting the expansion of affiliated medical institutions in 27
regions including Hokkaido, Kansai, Kyushu, etc., expecting the earnest
activation of the stem cell regenerative medical treatment in 2017.
Moreover, the company is planning to expand the area of medical
treatment to anti-aging and Alzheimer’s disease. The company expects to
perform regenerative medical treatment more than 5,000 times and supply
cells which will be worth more than 1.5 trillion won for this year.
From this March, production processes will be allocated to Nature
Cell and the affiliated company R
Bio, which received permission for manufacturing from Japan’s
Ministry of Health, Labor and Welfare. Japan BioStar Stemcell Research
Institute (Director: Jeong-chan Ra) will be established in the KOBE
Biomedical Innovation Cluster.
R-JAPAN Co., Ltd. is the advanced biotechnology company specialized in
manufacturing mesenchymal stem cells regenerative therapy with stem cell
technology of Biostar
Stem cell Research Institute in Korea. R-Japan’s proprietary
technology is to isolate, multiply, and store adult mesenchymal stem
cells with ensuring genetic integrity. R-Japan currently cultures
approximately 1,000 cases per month and has been evaluated by many
medical institutions. As a result, R-Japan has been cultured 5,860
billion cells for 24,293 patients since stem cell processing facility